Tailoring LDL-C-Lowering Therapy to Patient Cardiovascular Risk: Identifying Effective Strategies for Patients with Diabetes
Nov 30, 2019
Reducing LDL-C and Cardiovascular Risk with Nonstatin Therapy: From Evidence to Practice
Jul 02, 2019
Managing LDL-C to Reduce Cardiovascular Disease Risk: Defining Best Clinical Practice
Apr 22, 2019
LDL-Cholesterol Lowering and Atherosclerotic Cardiovascular Disease Risk Reduction: Exploring the Evidence With Non-Statin Therapy
Jun 17, 2018
Improving Outcomes in Patients with Elevated LDL-Cholesterol: A Case-Based Series
Jan 01, 2018
The Perfect Storm of Heart Failure and Diabetes: Insights into Pathophysiology and Evidence-Based Treatment Strategies
Nov 08, 2016
November 30, 2019
In this program, a panel of experts will discuss the latest guidelines for managing LDL-C in patients with diabetes, interpret data with nonstatin, LDL-C-lowering therapies, describe improving access to PCSK9 inhibitors and tips for achieving earlier access,
July 02, 2019
In this symposium, lipid experts Dr. Robert Giugliano, Dr. Marc Sabatine, and Dr. James Underberg will describe best practices for internists in managing LDL-C and reducing the risk for major cardiovascular events with the addition of nonstatin therapy.
No Credit Available
April 22, 2019
In this program, an expert faculty will discuss the evidence and recommendations for managing LDL-C in patients with ASCVD, familial hypercholesterolemia (FH), diabetes, and those at increased cardiovascular risk without ASCVD.
June 17, 2018
n this program, lipid experts will present, in state-of-the-art lectures and in 'realworld' interactive cases, optimal strategies and provide 'take-home' messages for reducing risk in patients with elevated LDL-C.
January 01, 2018
An informative expert series of lectures including cases with the goal of improving outcomes in patients with elevated LDL-cholesterol
November 08, 2016
In this educational initiative, experts will address the needs of cardiologists for 1) a grasp of the relationship between DM and HF and the pathophysiology of HF in DM, 2) an explanation of clinical evidence for HF drugs in patients with DM, and 3) an assessment of the profiles of traditional and newer antidiabetic agents in patients with/at risk for cardiovascular disease and interpretation of heart failure-related outcomes.
May 08, 2015
Deepak Bhatt, MD, MPH, FSCAI (Chair); Duane Pinto, MD, FSCAI and Peter Stone, MD, MPH conduct a state-of-the-art discussion and case study on recurrent angina after PCI